The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
CONFIDENTIAL Update for Rex Bionics PLC SHareholders May 8, 2018 Rex Bionics continues to make strides towards our market development activities in the key countries of the US, UK, AU and NZ as well as working towards the launch of REX in China. The company also continues to work toward a next product design that incorporates more of the specific needs of in patient rehab in stroke. In the US we have continued to make progress on our target list of customers identified to aid in maret development, and have recently received approval for extended clinical demonstrations at Columbia University and Mt Sinai Hospital in New York. We are awaiting approval at the Bronx VA. We have also completed product demos at other sites that will likely result in orders. Once devices are in these centers we plan to develop a clinical trial in stroke patients using the knowledge of these experts in designing and carrying out that clinical trial. In Australia we have been making good progress in the AIN clinical trial, the HELEN Project. We have also made progress with NeuroMoves in Sydney and are looking to future collaborations with them on clinical research that we hope to get grants to fund. We have multiple demonstrations set up and have just completed a big training round and have another one scheduled for June. In the UK we have been making great progress on RAPPER III, our multiple sclerosis clinical trials in East Kent with Dr. Mo Sakel. The data from the first phase was very encouraging and we hope to have final ethics committee approval for the next phase, RAPPER IV, in late May and enrolling patients in June. The paper from the first phase is being finalized and submitted for publication and has been submitted to ACRM for presentation in the fall. We have also finalized the final clinical paper for submission from the RAPPER II study. Again the results are very favorable and we are excited to get the paper published. We are very excited about the progress we are making with the Chinese FDA towards approval of REX in China. We had a panel meeting in October and received questions at the beginning of the year that are in the process of being finalized. We hope to have the final approval by the 3rd quarter and will begin commercialization at that point. We see the Chinese opportunity for the current REX as one of the most important opportunities for us and are focusing resources on that. We have also continued to make progress on the new product development. Working with McLaren we are coming up towards the end of the concept development phase and are spending time evaluating the concept as we make decisions on moving forward the design with our internal team supported by outside expertise provided by McLaren and others. We are excited about the quality of the thinking and work that has gone into the process that will result in a great next product for the company. To support those effort the compan
Being moved out of ISA status at Barclays .
in a few years no doubt .or an offer for our stock before that happens.
Let`s hope the listing in Australia goes ahead . Good luck
bbr331 .looks like they are straight to work with this now .job vacancy 26th may regulatory and quality manager position posted .see rex bionics linkedin.To achieve iso medical quality.
Good to know the work continues .
Rex on bbc look north..rexbionics facebook.
Thanks hink , The long wait begins again.
Australian translation fund together with bio managers have invested at 98p per share .mclaren warrants set at £1.44p .I know that australian fund are in it to make a profit as in effect using taxpayers money on this equity stake .Just think this was listed a few years to early .good luck bbr31 .
Seems like we both agree on this one . Let`s hope Trinity repeats . Good luck
Have a 44%stake in the rxb pty australia.bio managagers 22% rexbionics aim uk 36%.should still have some funding from callaghan new zealand as well 3fund managers have a pot of $500m between them to bring innovations to market..
yes bradshaw asset management had them .directly they own just under 18% and 478000 sharesi in another fund .victory fund .. victory fund paid i believe 30p per share in august 2016.managed to get some at 2.7p today. average circa 3.5p ..Probably see an aussie listing in the future .mclaren warrants at £1.44p. is interesting .Expect refloat 2019-2020 rights issue at some point and relisting .
LONDON (Alliance News) - Rex Bionics PLC on Friday said Hunter Hall Investment Management Ltd disposed of its entire stake in the business on Wednesday. The shareholder did have 3.8 million shares in the London-listed company, but now has nil. Rex Bionics shares closed down 80% on Friday at 0.50 pence. On Friday, the company completed a restructuring that will leave it operating as a cash shell and delisting from AIM, transferring its business and assets into its Australian subsidiary. Perhaps a reappearance in Australia is proposed. Good luck Hinkais et Al And May
500%??
money invested by them is i believe matched by the australian goverment to keep innovations in the country .A new initiative for promising biomed ventures .introduced late 2016 dyor.hence the move to rxb pty australia.
looks like all the ground work has been done trials etc .True value is yet to come .
just wondering what the cash position is here as any left over cash was not part of the deal .A specie payment possible or is the cash for the rights if any left.Another update is due anyway soon.
bbr391.Have you managed to buy any today?
The value investor .Buys stocks that are really undervalued not showing their true worth.
Both adding to their stock . Good luck All And May
Only 133.33%. Positively tight. And May
30p rights issue in 2years time imo load up .nothing of quantity to buy anyway.
Will be suspended from May 30th. De Listed from AIM June 30th. Continue Private ?? No notice of how any shares will be traded.. Best luck all..
You've already got your surprise they're down 40%.